Literature DB >> 23172518

The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients.

B Baudino1, F D'agata, P Caroppo, G Castellano, S Cauda, M Manfredi, E Geda, L Castelli, P Mortara, L Orsi, F Cauda, K Sacco, R B Ardito, L Pinessi, G Geminiani, R Torta, G Bisi.   

Abstract

AIM: A growing number of neuropsychological studies reported that chemotherapy may impair brain functions, inducing persistent cognitive changes in a subset of cancer survivors. The aim of this paper was to investigate the neural basis of the chemotherapy induced neurobehavioral changes by means of metabolic imaging and neuropsychological testing.
METHODS: We studied the resting brain [¹⁸F]FDG-PET/CT images of 50 adult cancer patients with diagnosis of lymphoma: 18 patients were studied prior and 32 after to chemotherapy. All patients underwent to a neuropsychological examination assessing cognitive impairment (tests for shifting attention, verbal memory, phonemic fluency), depression, anxiety and distress.
RESULTS: Compared to no chemotherapy patients, the treated group showed significant bilateral lower rate of glucose metabolism in prefrontal cortices, cerebellum, medial cortices and limbic brain areas. The metabolism of these regions negatively correlated with number of cycles and positively with post-chemotherapy time. The treated group showed a poorer performance in many frontal functions, but similar level of depression, anxiety and distress.
CONCLUSIONS: Chemotherapy induced significant long-term changes in metabolism of multiple regions with a prevailing involvement of the prefrontal cortex. The observed cognitive dysfunctions could be explained by these changes. The recovery from chemotherapy is probably affected by treatment duration and by the time elapsed after its end. We speculated that the mechanism could be an accelerating ageing / oxidative stress that, in some patients at risk, could result in an early and persistent cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23172518

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  22 in total

Review 1.  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Authors:  Annalynn M Williams; Clive S Zent; Michelle C Janelsins
Journal:  Br J Haematol       Date:  2016-07-08       Impact factor: 6.998

2.  Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism.

Authors:  E Peila; F D'Agata; P Caroppo; L Orsi; P Mortara; S Cauda; M Manfredi; M M Caglio; P Fenoglio; B Baudino; G Castellano; G Bisi; L Pinessi; S Gallone
Journal:  Neurotox Res       Date:  2016-06-07       Impact factor: 3.911

3.  Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients.

Authors:  D E Anderson; V R Bhatt; K Schmid; S A Holstein; M Lunning; A M Berger; M Rizzo
Journal:  Clin Neurophysiol       Date:  2019-05-24       Impact factor: 3.708

4.  Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis.

Authors:  Nicolas Aide; Thibault Salomon; Charline Lasnon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-14       Impact factor: 9.236

Review 5.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 6.  Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors.

Authors:  Xiaojia Ren; Diana Boriero; Luksana Chaiswing; Subbarao Bondada; Daret K St Clair; D Allan Butterfield
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-02-10       Impact factor: 5.187

7.  Cognitive function and its relationship to other psychosocial factors in lymphoma survivors.

Authors:  Dorothy Krolak; Barbara Collins; Lorelle Weiss; Cheryl Harris; Richard Van der Jagt
Journal:  Support Care Cancer       Date:  2016-11-11       Impact factor: 3.603

Review 8.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

9.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

10.  Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study.

Authors:  David E Anderson; Sachin Kedar; Vijaya R Bhatt; Kendra Schmid; Sarah A Holstein; Matthew Rizzo
Journal:  J Neurol Sci       Date:  2019-12-24       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.